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Treatment of glioblastoma multiforme (GBM) and brain metastasis remains a challenge
because of the poor survival and the potential for brain damage following radiation. Despite
concurrent chemotherapy and radiation dose escalation, local recurrence remains the pre-
dominant pattern of failure in GBM most likely secondary to repopulation of cancer stem
cells. Even though radiotherapy is highly effective for local control of radio-resistant tumors
such as melanoma and renal cell cancer, systemic disease progression is the cause of
death in most patients with brain metastasis. Preservation of quality of life (QOL) of cancer
survivors is the main issue for patients with brain metastasis. Image-guided radiotherapy
(IGRT) by virtue of precise radiation dose delivery may reduce treatment time of patients
with GBM without excessive toxicity and potentially improve neurocognitive function with
preservation of local control in patients with brain metastasis. Future prospective trials
for primary brain tumors or brain metastasis should include IGRT to assess its efficacy to
improve patient QOL.
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INTRODUCTION
Treatment of glioblastoma multiforme (GBM) and brain metas-
tasis remains a challenge because the poor survival and potential
for brain damage. Despite the fact that GBM is a primary glioma
and brain metastasis represents dissemination to the brain of solid
malignant tumors, median survival for both conditions remains
similar because of the lack of treatment efficacy. Prognosis fac-
tors for both GBM and brain metastasis are age and performance
status based on the recursive partitioning analysis (1, 2). Thus,
given the remote chance for long-term survival, the goal of treat-
ment should be the improvement of quality of life (QOL) for
GBM and brain metastasis patients. New radiotherapy techniques
such as image-guided radiotherapy (IGRT) provides the clinician
with an unique opportunity to shorten the length of treatment
without increasing treatment toxicity by virtue of normal tissue
sparing. Magnetic resonance imaging (MRI) is now integrated
into of radiotherapy planning to improve treatment accuracy.
New imaging modalities such as positron emission tomography
(PET) and diffusion tensor imaging (DTI) may also accurately
delineate the gross tumor volume (GTV) and the areas of radia-
tion brain damage respectively, and complement MRI to decrease
normal tissue toxicity. In the following sections, we will review
the literature to determine how to best combine new diagnos-
tic technology with advanced radiation treatment to improve
patient QOL.
TREATMENT OF GLIOBLASTOMA
Standard treatment for GBM is surgical resection if feasible fol-
lowed by concurrent chemotherapy with temozolomide (TMZ)
and radiation (3). Despite the addition of TMZ, only 9.8% of the
patients survived at 5 years. The predominant pattern of recur-
rence is local failure suggesting that improving local control may
improve survival. Many institutions have attempted to increase
radiation dose to the tumor bed for better local control. How-
ever, a randomized study using radiosurgery as a boost dose to
the tumor bed prior to chemoradiation did not demonstrate
any improvement of survival. Two hundred and three patients
with supratentorial GBM were randomized between carmustine
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(BCNU) and standard radiation to 60 Gy or radiosurgery boost
followed by standard radiation. Local failures occurred in 90%
for both groups causing patient death (4). These clinical results
suggest that GBM is both chemo- and radio-resistant. Recent
studies in molecular biology have demonstrated the existence
of cancer stem cells (CSCs) in GBM responsible for treatment
failure. Despite high doses of radiation of 30–60 Gy in a sin-
gle fraction, these CSCs continued to proliferate in cell cultures
following radiation (5). The radio-resistance of GBM cells sug-
gests that radiation dose escalation alone is not feasible to control
tumor growth in the clinical setting because of the excessive neu-
rotoxicity associated with such a high dose. The mechanism of
chemo-resistance of CSCs is complex but one of the principal
mechanisms is the presence of transporters that actively pump
the drugs out of the cells preventing their tumoricidal actions
(6). Thus, unless new therapies are directed toward the control
of CSCs, conventional postoperative chemotherapy and radia-
tion is doomed to fail. A reasonable alternative to the standard
fractionation schedule would be shortening the course of radio-
therapy which may allow the patient to spend quality time with
their family provided that the accelerated course does not increase
toxicity. A randomized trial of TMZ versus standard radiother-
apy versus hypo-fractionated radiotherapy in elderly patients
showed a better survival in patients above 70 years treated by
hypo-fractionated radiotherapy or TMZ as compared to standard
radiotherapy (7).
TREATMENT OF BRAIN METASTASES
Even though the optimal treatment for brain metastasis remains
controversial, radiation therapy is very effective to prevent disease
progression even for radio-resistant tumors such as renal cell can-
cer and melanoma. The delivery of a very high radiation dose with
radiosurgery provides excellent local control (8). However, when
there are multiple metastases or when there is evidence of tumor
progression after radiosurgery, whole brain radiotherapy (WBRT)
is required. In patients who had tumor regression following whole
brain irradiation, neurocognitive function, and survival improve
suggesting that local control of the tumor in the brain remains the
most important factor to prevent deterioration of mental status
(9). Even though ultimately all patients experienced deterioration
of their neurocognitive function following radiosurgery alone or
radiosurgery with WBRT, improvement of local control with the
addition of WBRT delayed the time to deterioration emphasiz-
ing the importance of local control on mental status (10). There
are still controversies whether WBRT should be added to radio-
surgery for brain metastasis at initial diagnosis. In one study, the
poor survival observed with WBRT and radiosurgery compared
to radiosurgery alone is most likely due to the delay to initiate
chemotherapy in patients who received WBRT (11). Most of the
patients treated for brain metastasis ultimately died from systemic
disease progression emphasizing the fact that while local control
remains important, chemotherapy remains the main treatment
and should not be delayed unnecessarily (12). Thus, future stud-
ies should focus on decreasing the overall treatment time and the
neurotoxicity of WBRT while optimizing local control of brain
metastases.
RADIATION-INDUCED NEUROTOXICITY
Animal experiments demonstrate normal brain injury following
WBRT. Adult rats exposed to single fraction whole brain irradi-
ation to 25 Gy developed decreased cognitive function compared
to sham-irradiated rats (13). Autopsy of the irradiated rat brains
revealed demyelination with or without necrosis mainly in the
corpus callosum. Increased gliosis was also observed similar to
the one reported in human brains affected by accelerated aging
such as Alzheimer’s disease and multiple sclerosis. Damage to
the normal brain is dose-dependent as adults rats exposed to
whole brain fractionated irradiation to 30 Gy in 10 fractions devel-
oped memory loss without observed microscopic damage (14).
The mechanism of brain injury at the molecular level is com-
plex and is postulated secondary to depletion of oligodendrocytes
leading to demyelination, deletion of neural stem cells (NSCs)
in the hippocampus, cerebral cortex, vascular injury, and more
recently vasculitis (15, 16). The use of MRI-based techniques such
as DTI allows for monitoring of human brain damage following
irradiation. DTI measures water molecule diffusion in the brain
which varies with the direction, density, and myelination of white
matter fibers. Diffusion of water perpendicular and parallel to
white fibers is termed radial diffusivity (RD) and axial diffusivity
(AD) respectively. Increased RD and decreased AD has been cor-
related to decreased myelination and increased gliosis respectively.
Using DTI prior to and 1 month post WBRT in 14 patients with
brain metastases, increased RD was observed in all brain struc-
tures but more prominent in the cingula and fornix suggesting
demyelination of the limbic structures responsible for memory
and behavior (17). Radiation-induced demyelination of the white
matter tract was also corroborated in another study also show-
ing a heterogeneous extent of injury despite a uniform radiation
dose suggesting that some white matter tracts are more sensitive
than others (18). An autopsy case report of a patient dying follow-
ing radiation myelopathy also demonstrated extensive demyelina-
tion and axonal loss without vascular damage corroborating the
DTI report (19). In addition, WBRT or partial brain irradiation
damages the NSCs which usually remain dormant within the sub-
ventricular zone. Following a moderate radiation dose of 4 Gy,
NSCs start to proliferate exposing them to death from apoptosis
with higher radiation doses (20, 21). Animal experiments demon-
strated a direct relationship between radiation damage to NSCs
and neurocognitive dysfunction. Rats receiving WBRT developed
cognitive dysfunction but if they were transplanted with NSCs
in the hippocampus after radiation, the ones who received NSCs
recovered their cognitive function compared to the ones who
had sham surgery (22). The transplanted NSCs migrated exten-
sively and differentiated into glial and neuronal lineages of the
rat brain even though they were from human species suggesting
that 1 day, human NSC transplants may be used to treat neu-
rocognitive damage following brain irradiation (22). In another
mouse model delivering a high radiation dose to the whole brain
(20 Gy in 4 Gy/fraction) similar to the clinical whole brain treat-
ment, the mice developed short term memory loss associated with
decreased granular layer of the dentate gyrus of the hippocampus.
However, if the irradiated mice received NSCs administered intra-
venously following each radiation treatment, they preserved both
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brain structure and function (23). Autopsy of patients who had
WBRT also demonstrated depletion of neuronal cells in the hip-
pocampus (24). Thus, protecting the limbic system from excessive
radiation may reduce neurocognitive damage following WBRT.
CURRENT IMPACT OF MRI ON RADIOTHERAPY TREATMENT
PLANNING
Because of the non-ionizing technique that uses a strong magnetic
field to provide high resolution anatomic information, MRI is now
integrated into the radiotherapy planning for brain tumors. The
accuracy of MRI to demonstrate tumor invasion of the normal
organs has led to the development of MRI-based linear accel-
erators. Institutional preference dictates the choice of either T2-
weighted MRI or FLAIR MRI to outline the GTV and surrounding
edema as CTV. Traditionally T2-weighted MRI has been used as
GTV delineation because biopsy of the area of MRI T2 abnor-
mality demonstrated tumor cells outside of contrast enhanced CT
abnormality. However, T2 weighting causes cranial spinal fluid
(CSF) to be brighter which may potentially impair visualization
of the GTV. The FLAIR sequence nullifies the CSF signal and may
provide better GTV delineation. An expansion of 2 cm of the CTV
is used to outline PTV. The FLAIR PTV is usually larger than the
T2 PTV and may potentially increase normal tissue toxicity (25).
On the other hand FLAIR images provides better tumor-to-CSF
contrast compared to T2 and T1 weighted sequences and may be
valuable for stereotactic planning of brain gliomas and metastases
(26). Thus, incorporating FLAIR sequence into radiotherapy plan-
ning may potentially improve tumor targeting for radiation dose
escalation.
The introduction of higher field strength MRI (3.0 T) (3T MRI)
compared to the conventional 1.5 T (1.5T MRI) may potentially
increase radiotherapy delivery accuracy because of higher image
resolution. In a study of 138 patients with brain metastases, 22%
were found to have a higher number of metastases with 3 T MRI
compared to 1.5 T MRI. All patients were treated with radiosurgery
with the radiotherapy planning based on 3 T MRI and would have
had geographic miss if 1.5 T MRI was used for treatment plan-
ning (27). Patients with multiple brain metastases are more likely
to have additional lesions seen on 3 T MRI (28). The superior-
ity of 3 T MRI for radiosurgery planning compared to 1.5 T MRI
was also corroborated in another study (29). Thus, even though
these studies are only preliminary, 3 T MRI may have an increasing
importance in the future for radiotherapy planning.
POTENTIAL ROLE OF O-(2-[18F]-FLUOROETHYL-L-TYROSINE
POSITRON EMISSION TOMOGRAPHY IN RADIOTHERAPY
PLANNING AND TREATMENT OF GBM
Accurate tumor delineation is the first step in radiotherapy plan-
ning to avoid marginal miss and to decrease excessive radiation
dose to the critical structures adjacent to the tumor. Standard
imaging for neurologic oncology has been MRI with gadolin-
ium contrast. The extent of contrast enhancement on MRI is
used to determine the GTV or as an indicator of therapeutic
response. However, contrast enhancement due to the transient
blood brain barrier breakdown following surgery, may mimic
tumor progression and interfere with the GTV delineation. O-
(2-[18F]-fluoroethyl-l-tyrosine (FET) is an amino acid analog
radiolabeled with fluorine 18. After crossing the blood brain bar-
rier, FET is taken by LAT2 transporters located on the membranes
of the GBM cells. Thus, high uptake of FET by the tumor cells
allows for better visualization of the tumor compared to the
normal brain. The advantages of FET include its long half-life
(110 min), its ease for synthesis, its fast brain and tumor uptake
kinetics, and low accumulation in non-tumor tissues making this
radiotracer an ideal imaging technique in the outpatient setting
(30). Because the tumor uptake of FET is independent of blood
brain barrier disruption, FET-PET may be complementary to MRI
to outline the exact extension of the tumor and serve as func-
tional imaging for IGRT. In a study of 17 patients with biopsy
proven GBM, FET-PET was compared to MRI for GTV delin-
eation. The GTV based on FET-PET was larger in 10 patients,
smaller in three, and the same in the remaining four (31). Per-
haps, the major advantage of FET-PET over conventional MRI for
radiotherapy planning is its ability to detect areas of high tumor
activity within the GTV which manifest as a high standard uptake
value (SUV) (32). These high SUV areas can be targeted with a
higher radiation dose compared to the dose delivered to the GTV,
thus potentially increasing tumor control without increasing radi-
ation dose to the normal brain tissue. The main weaknesses of the
clinical studies which failed to demonstrate a survival benefit for
dose escalation in GBM are their reliance on MRI for target delin-
eation and the radiotherapy technique employed which delivered
a uniform dose across the GTV. The tumor concentration within
the GTV is heterogeneous and areas with high concentration of
actively dividing tumor cells may have residual tumor cells after
radiation. On the other hand, increasing tumor dose to improve
local control may lead to severe complications because of excessive
irradiation of the adjacent normal brain tissue. Thus, a radiation
technique that allows radiation dose escalation within the tumor
without increasing the dose to the normal brain would be ideal.
Integrating FET-PET into IGRT planning may be a solution to
avoid neurotoxicity. As an illustration, the dosimetric advantage
of IGRT with the simultaneous integrated boost (SIB) technique
to spare the normal brain compared to the conventional sequen-
tial (SEQ) boost technique for primary brain tumors was reported
recently (33). Other advantages of FET-PET are its better accu-
racy compared to MRI allowing better local control because of
decreased risk of marginal miss and better ability to detect tumor
after radiation (31, 34). FET-PET will likely play a prominent role
in future IGRT studies for brain tumors.
TECHNOLOGIES OF IGRT DELIVERY
There are currently two systems for IGRT delivery which are
grouped into radiation-based (kV and MV) and non-radiation
based (ultrasound, electromagnetic) (35). Visualization of the
tumor is either direct or through fiducial markers inserted into
the tumor. The images acquired before the treatment are then
compared to the ones acquired during radiotherapy planning. A
shift in patient position is performed if there is any discrepancy in
the set up and another set of images is obtained to verify treatment
accuracy. Thus, daily imaging minimizes the risk for marginal miss
due to positioning and patient movement during treatment. It is
unclear which imaging modality is optimal for IGRT delivery. The
choice of the IGRT technology most likely depends on clinician
www.frontiersin.org November 2013 | Volume 3 | Article 284 | 3
Nguyen et al. IGRT and brain tumors
preference, the types of tumors most commonly treated at the
radiation oncology institution, and budget constraints.
In the radiation based system, the image acquired prior to
treatment are either 2-dimensional (2D) or 3-dimensional (3D).
The quality of image is superior with kV imaging compared to
MV imaging. Image acquisition in the 2D system relies on elec-
tronic portal imaging devices (EPIDs) where the treatment beam is
captured on a flat panel behind the patient (Clinac, Elekta Oncol-
ogy Primus) and stereotactic imaging. The stereotactic imaging
relies on two kV X-ray sources mounted on ceiling or floor which
provides orthogonal images and real time imaging (CyberKnife,
Novalis TX, BrainLab). Even though the image quality is excel-
lent, stereotactic imaging relies on bony landmarks or surrogate
markers and does not provide soft tissue information. The kVCT
(fan beam) imaging uses a diagnostic CT scan along side the lin-
ear accelerator (CT on rails, Siemens Medical Systems; ExaCT,
Varian Medical Systems). Soft tissue information is excellent with
the kVCT fan beam but the couch needs to be displaced between
imaging and treatment which may lead to positioning error. The
kVCT (cone beam) uses an gantry mounted kV source and a flat
panel detector. A series of kV X-rays are taken when the gantry
rotates and a 3D image is reconstructed. Even though the soft tis-
sue special resolution is good, the image quality is inferior to fan
beam kV CT (Synergy, Elekta; On Board Imager, Varian Medical
Systems; Artiste, Siemens Medical Systems). In the MV CT fan
beam system, the imaging is performed by the treatment beam
which rotates around the patient while the couch moves (Helical
Tomotherapy). There is no metal artifacts but the image quality is
inferior to kV CT.
In the non-radiation based system, an ultrasound is performed
before the treatment for target localization (usually prostate). The
system is simple, non-invasive, inexpensive but operator depen-
dent (Varian Medical Systems, B Mode Acquisition, and Tar-
geting; Nomos, Elekta Oncology). Another non-radiation based
system relies on the implantation of electromagnetic transponders
inserted in the target (usually prostate) which provides tracking of
the tumor motion (Calypso). The last non-radiation based system
which is just approved by the US Food and Drug Administration
involves a hybrid MRI and Cobalt linear accelerator (ViewRay)
may have promising potential for brain tumors because of the
imaging quality but needs to be confirmed in future clinical trials.
CLINICAL STUDIES DEMONSTRATING THE POTENTIAL ROLE
OF IGRT IN THE TREATMENT OF GBM
The combination of better tumor delineation, daily treatment
imaging, and sharp dose gradient makes IGRT an ideal tool for
radiotherapy because of the potential for dose escalation and
reduced toxicity to the normal brain compared to 3-dimensional
conformal radiotherapy (3D-CRT). As most studies failed to
demonstrate an improvement in local control and survival in
GBM patients with radiation dose escalation because of the tumor
radio-resistance, accelerated radiation treatment may provide the
patient with a better QOL and more quality time with their loved
ones if the shortened treatment is equally effective compared to
the conventional fractionation (30 days of radiotherapy). Prelim-
inary studies of intensity-modulated radiotherapy (IMRT) for
GBM demonstrated the feasibility of this treatment alternative.
A total of 24 patients with resected GBM received postoperative
hypo-fractionated IMRT to the surgical cavity and residual tumor
to 60 Gy in 10 fractions (6 Gy/fraction) and concurrent TMZ. The
median survival was 16 months comparable to historic control in
patients treated with conventional fractionation (36). Other stud-
ies also corroborated the efficacy and safety of hypo-fractionated
IMRT for GBM (37). Compared to IMRT, IGRT may allow for
reduction of the planning target volume because of daily pre-
treatment imaging and the accuracy of the technique. Thus, IGRT
is particularly useful when the tumor is located close to critical
radiosensitive structures such as the optic chiasm,optic nerves, and
brain stem. IGRT has been used as a boost dose for these indica-
tions to deliver a high dose to the tumor bed without increasing the
risk of complications (38). Patients with GBM close to radiosen-
sitive structures can also be treated with IGRT through the whole
course of treatment with the SIB technique delivering a higher
dose to the tumor (66 Gy instead of 60 Gy) without any compli-
cations (39). The course of radiotherapy can also be reduced to
three to six treatments with IGRT without excessive toxicity (40).
Other studies also corroborated the efficacy and safety of hypo-
fractionated IGRT for GBM with fractionation ranging from one
to eight treatments (41, 42).
The best illustration of the indication for IGRT in the treat-
ment of GBM may be its role in the re-irradiation of recur-
rent tumor following standard chemoradiotherapy. Depending
on tumor size, a single or multiple fractions may be delivered
with IGRT for salvage. The steep dose gradient between the
tumor and surrounding tissues decreases the risk of brain radio-
necrosis. Median survival following salvage IGRT ranges from
7 to 11 months with or without chemotherapy (43–47). Toxic-
ity of IGRT for re-irradiation remains acceptable. As most IGRT
studies for recurrent GBM were based on MRI for tumor delin-
eation, it would be interesting to see if integrating FET-PET into
radiotherapy planning would improve local control and survival.
A preliminary study PET study using 11C Methionine, a radiola-
beled amino acid with a shorter half-life compared to FET, suggests
that the median survival of patients with recurrent GBM under-
going molecular imaging for radiotherapy planning is superior
to the ones of patients who had conventional MRI (48). Median
survival was respectively 9 and 5 months for IGRT with and with-
out biological imaging. The data is intriguing and merits further
investigation.
CLINICAL STUDIES DEMONSTRATING THE POTENTIAL ROLE
OF IGRT IN THE TREATMENT OF BRAIN METASTASIS
As survival of patients with brain metastasis depends on the con-
trol of systemic disease, it would be logical to provide radiotherapy
within a short time frame to avoid delay in initiating chemother-
apy. Radiosurgery would be one option because treatment would
be delivered in one fraction. The caveat of radiosurgery is the high
risk of recurrence in the non-treated areas of the brain. Adding
WBRT may decrease the risk of recurrence in other areas of the
normal brain but may worsen neurocognitive function and delay
chemotherapy. The ideal treatment for brain metastases would be
a combination of high radiation to the tumor, a reasonable treat-
ment time to allow chemotherapy initiation, and preservation of
neurocognitive function if feasible.
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Preliminary studies of whole brain IGRT with SIB to the brain
metastases have been very encouraging. A phase I study of 48
patients with one to three brain metastases reported no increased
toxicity when the whole brain was treated to 30 Gy in 3 Gy/fraction
while the brain metastases were treated on a dose escalation sched-
ule ranging from 35 Gy (3.5 Gy/fraction) to 60 Gy (6 Gy/fraction).
Only 8 out of 48 patients (14%) developed progressive disease in
the brain (49). A later pooled analysis of 120 patients with brain
metastasis confirmed the safety of this approach. Seventy patients
with one to three brain metastases were treated according to the
previous protocol of 30 Gy in 3 Gy/fraction to the whole brain and
50 patients with one to six brain metastases were treated to 20 Gy
in 4 Gy/fraction to the whole brain and 40 Gy in 8 Gy/fraction to
the brain metastases (50). Twenty-one patients (23%) died from
intracranial disease progression. Three patients developed tumor
necrosis but there was no death from treatment toxicity. Thus,
whole brain IGRT with SIB seemed to achieve good local control
for patients with one to six brain metastases within 1–2 weeks
of radiotherapy. The absence of toxicity of whole brain IGRT
with SIB was also corroborated in another study. Twenty-nine
patients with one to four brain metastases were treated to 30 Gy
in 3 Gy/fraction to the whole brain and 40 Gy in 4 Gy/fraction to
the brain metastases (51). QOL and neurocognitive function were
also tested. Three patients (13%) developed local failures. There
was no impairment of neurocognitive function but QOL deteri-
orated 3 months after treatment. The cause of death in all three
IGRT whole brain studies were predominantly systemic disease
progression emphasizing the need for systemic disease control in
patients with brain metastasis.
To protect long-term survivors from neurocognitive dysfunc-
tion following WBRT, sparing of the limbic system from excessive
radiation should be considered. Technically, it is feasible to spare
the hippocampus and NSCs compartment with IGRT without
under-dosing the target volume (52, 53). Animal experiments
demonstrated the feasibility of NSC sparing IMRT. Mice receiving
NSC sparing IMRT developed less damage to the NSC com-
pared to a non-sparing NSC technique (54). Thus, it would be
interesting to combine whole brain IGRT with SIB and hippocam-
pus sparing in patients with brain metastases to improve local
control and preserve neurocognitive function in future clinical
trials.
We emphasize that radiation dose escalation for brain tumors
and brain metastasis should not be performed without appropriate
image guidance because of the potential for increased neurotox-
icity. Preliminary evidence suggests that when combined with
advanced tumor imaging such as PET scan, IGRT may provide
excellent loco-regional control while sparing normal organs from
excessive radiation toxicity in patients with locally advanced head
and neck cancer (55, 56). As an illustration, even a small organ such
as the cochlea can be shielded from radiation when the gross neck
nodes were treated to a curative dose of radiation (70 Gy). This
may potentially decrease the risk of hearing loss (57). Similarly,
IGRT, when applied incranially, may potentially maximizing nor-
mal neuro-tissue sparing, and potentially improves the patient’s
QOL in patient with primary brain tumors and brain metastasis
and needs to be investigated in future prospective studies.
CONCLUSION
Image-guided radiotherapy is a promising technique to reduce
treatment time in patients with GBM. In the future FET-PET
may further improve treatment accuracy of IGRT and potentially
improve local control. In patients with brain metastases, whole
brain IGRT with SIB may allow improvement of local control
and early initiation of systemic therapy for better survival. Spar-
ing of the hippocampus with whole brain IGRT is intriguing and
merits further investigation to preserve neurocognitive function.
Prospective studies should be performed to investigate the feasi-
bility of IGRT to improve QOL in patients with GBM or brain
metastasis.
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